QuantaMatrix Inc. (KOSDAQ:317690)

Market Cap	79.02B
Revenue (ttm)	2.50B
Net Income (ttm)	-20.17B
Shares Out	18.08M
EPS (ttm)	-1,220.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	452,779
Average Volume	141,768
Open	4,155.00
Previous Close	4,195.00
Day's Range	4,155.00 - 4,640.00
52-Week Range	3,360.00 - 23,700.00
Beta	0.15
RSI	38.60
Earnings Date	Mar 21, 2025

About QuantaMatrix

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded i...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2010
• Employees: 91
• Stock Exchange: KOSDAQ
• Ticker Symbol: 317690

Financial Performance

In 2023, QuantaMatrix's revenue was 3.12 billion, an increase of 142.47% compared to the previous year's 1.29 billion. Losses were -21.56 billion, 12.1% more than in 2022.